ABSTRACT

Tigecycline is a broad-spectrum antibiotic agent used to treat severe or multidrug-resistant (MDR) bacterial infections. Bacterial infection is a common and severe complication or comorbidity associated with end-stage renal disease (ESRD). However, few cases have been reported regarding the adverse drug reactions of tigecycline in patients with ESRD. Here, we detail the case of a 19-year-old female with ESRD, who received tigecycline to treat her sepsis due to an MDR Staphylococcus aureus. Following 7 days of tigecycline, the patient developed coagulopathy with hypofibrinogenaemia, although there was no subsequent haemorrhage. The hypofibrinogenaemia resolved within 14 days after the discontinuation of tigecycline. Therefore, we recommend that clinicians strictly monitor the coagulation parameters in patients with ESRD during tigecycline treatment.